What is BMRN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 10.61B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BMRN?

P/E (TTM) is 145.36 and 52-week range is $49.26 to $70.98 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BMRN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BMRN?

The company profile lists revenue (TTM) near $3.39B, net income (TTM) near $72M, EPS (TTM) near $0.36 when available from the market-data feed. Figures are informational and may lag live markets.

Where is BioMarin Pharmaceutical Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Rafael California, California, US, 193.3M shares outstanding, ISIN US09061G1013 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

BioMarin Pharmaceutical Inc

$BMRN

Health Care · Biotechnology

IR Run Scenarios

$54.80

-0.17%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.

Employees

3,221

Website

www.biomarin.com/

IPO

1999-07-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)